Cellectar Biosciences (CLRB) and Aralez Pharmaceuticals (ARLZ) Critical Comparison
Cellectar Biosciences (NASDAQ: CLRB) and Aralez Pharmaceuticals (NASDAQ:ARLZ) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, institutional ownership, dividends and valuation.
This is a summary of current recommendations and price targets for Cellectar Biosciences and Aralez Pharmaceuticals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Cellectar Biosciences presently has a consensus price target of $2.70, indicating a potential upside of 58.82%. Aralez Pharmaceuticals has a consensus price target of $8.00, indicating a potential upside of 327.81%. Given Aralez Pharmaceuticals’ higher probable upside, analysts clearly believe Aralez Pharmaceuticals is more favorable than Cellectar Biosciences.
Risk & Volatility
Cellectar Biosciences has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500. Comparatively, Aralez Pharmaceuticals has a beta of 1.34, suggesting that its share price is 34% more volatile than the S&P 500.
Earnings and Valuation
This table compares Cellectar Biosciences and Aralez Pharmaceuticals’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Cellectar Biosciences||N/A||N/A||-$10.78 million||($1.24)||-1.37|
|Aralez Pharmaceuticals||$87.22 million||1.43||-$55.02 million||($1.64)||-1.14|
Cellectar Biosciences has higher revenue, but lower earnings than Aralez Pharmaceuticals. Cellectar Biosciences is trading at a lower price-to-earnings ratio than Aralez Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
2.6% of Cellectar Biosciences shares are held by institutional investors. Comparatively, 23.8% of Aralez Pharmaceuticals shares are held by institutional investors. 10.2% of Cellectar Biosciences shares are held by insiders. Comparatively, 6.7% of Aralez Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This table compares Cellectar Biosciences and Aralez Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Aralez Pharmaceuticals beats Cellectar Biosciences on 7 of the 11 factors compared between the two stocks.
About Cellectar Biosciences
Cellectar Biosciences, Inc., formerly Novelos Therapeutics, Inc., is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery platform. Its pipeline consists of pre-clinical and clinical product candidates, including radiotherapeutic and chemotherapeutic PDC’s. The Company’s PDC product portfolio includes CLR 131, which is designed to deliver cytotoxic (cell-killing) radiation directly and selectively to cancer cells and cancer stem cells; CLR 125, which is for the treatment of micro metastatic disease; CLR 124, which is a cancer-targeting positron emission tomography (PET) imaging PDC; CLR 1502, which is for intraoperative tumor margin illumination and non-invasive tumor imaging, and CTX Product Portfolio, including CLR 1601-PTX, CLR 1602-PTX and CLR 1603-PTX product candidates.
About Aralez Pharmaceuticals
Aralez Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G. Its development products include YOSPRALA and Bilastine. Fibricor (fenofibric acid) is indicated as a complementary therapy along with diet for the treatment of hypertriglyceridemia, and as a complementary therapy along with diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG) and apolipoprotein B (Apo B). Fibricor is also used to increase high-density lipoprotein (HDL) cholesterol (HDL-C) in patients with hypercholesterolemia or mixed dyslipidemia. Cambia (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug (NSAID).
Receive News & Stock Ratings for Cellectar Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectar Biosciences Inc. and related stocks with our FREE daily email newsletter.